TB-500 vs Sh-Polypeptide-1

TB-500 and Sh-Polypeptide-1 represent distinct classes of research peptides with overlapping yet divergent applications. TB-500, a synthetic fragment of thymosin beta-4, is primarily investigated for its roles in wound healing, inflammation modulation, and cardiac repair, supported by a handful of human randomized controlled trials. Sh-Polypeptide-1, the INCI designation for recombinant human epidermal growth factor (rh-EGF), is widely used in cosmetic formulations for anti-aging and skin renewal, but its clinical evidence specific to this designation is limited, relying heavily on broader EGF research. This comparison clarifies their mechanisms, evidence bases, and practical considerations for researchers deciding between them.

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found throughout human tissues. TB-500 contains the active healing region (sequence: Ac-LKKTETQ, MW ~889 g/mol) responsible for cell migration and tissue repair. It has a handful of human RCTs for wound healing and dry eye, plus a dedicated safety trial in 40 healthy adults showing minimal adverse effects. Despite this, it remains unapproved for human therapeutic use in all major markets and is banned by WADA and in horse racing.

Key claims: Accelerates wound healing; Reduces inflammation; Promotes cardiac repair.

Sh-Polypeptide-1 is the INCI designation for recombinant human epidermal growth factor (rh-EGF), produced via bioengineering in E. coli or yeast systems. It is functionally identical to natural EGF, binding to the EGF receptor to stimulate cell proliferation, differentiation, and migration. In cosmetic research, it is studied for anti-aging and skin renewal, with evidence suggesting it improves skin texture, reduces wrinkle depth, and accelerates wound healing. However, clinical evidence specific to the Sh-Polypeptide-1 designation is sparse; most supporting data derive from broader EGF research, including topical formulations and wound care studies. It differs from oligopeptide-1 primarily in nomenclature and regulatory classification, not biological activity. Key claims include anti-aging effects and enhanced skin regeneration, though direct human trials for this specific peptide are limited.

TB-500 and Sh-Polypeptide-1 target distinct research areas with minimal overlap. TB-500 is primarily investigated for injury recovery, including wound healing, muscle repair, and anti-inflammatory effects, with studies focusing on cardiac and soft tissue regeneration. Sh-Polypeptide-1 is predominantly studied in anti-aging skincare, with applications in dermal renewal, collagen synthesis, and cosmetic wound healing. While both peptides have been explored for wound healing, their mechanisms differ: TB-500 promotes cell migration via actin binding, whereas Sh-Polypeptide-1 stimulates proliferation via EGF receptor signaling. Researchers should select based on their specific focus—TB-500 for systemic tissue repair or Sh-Polypeptide-1 for topical skin applications.

TB-500: A safety-focused randomized controlled trial in 40 healthy adults (2010) found minimal adverse effects with synthetic thymosin beta-4. Published human and animal studies report no significant safety concerns, with common anecdotal side effects including injection site pain, redness, lightheadedness, mild headache, nausea, and fatigue. It remains unapproved for therapeutic use.

Sh-Polypeptide-1: Its safety profile aligns with EGF—generally well tolerated when applied topically. No significant adverse effects have been reported in cosmetic use, and bioengineering allows for high purity standards. However, systemic effects from topical application are minimal, and long-term safety data specific to this designation are lacking.